Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis - OMERACT validation of two whole-body MRI methods

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 651 KB, PDF-dokument

  • Marie Wetterslev
  • Robert GW Lambert
  • Walter P. Maksymowych
  • Iris Eshed
  • Susanne J. Pedersen
  • Paul Bird
  • Maria S. Stoenoiu
  • Simon Krabbe
  • Ashish J. Mathew
  • Violaine Foltz
  • Frédérique Gandjbakhch
  • Joel Paschke
  • Gabriele De Marco
  • Helena Marzo-Ortega
  • Philippe Carron
  • Anna EF Poulsen
  • Jacob L. Jaremko
  • Philip G. Conaghan
  • Østergaard, Mikkel

Objective: To validate reliability, correlation and responsiveness of two whole-body MRI scores for the hip/pelvis region in spondyloarthritis. Methods: Assessment of hip/pelvis inflammation in 4 multi-reader exercises using the OMERACT MRI Whole-body score for Inflammation in Peripheral joints and Entheses (MRI-WIPE) and Hip Inflammation Magnetic Resonance Imaging Scoring System (HIMRISS). Results: In exercises 3–4 (11/20 cases, respectively; 9 readers) reliability was mostly good for the 3 best calibrated readers. Median pairwise single-measure ICC for status were 0.58–0.65 (WIPE-osteitis), 0.10–0.88 (HIMRISS-osteitis) and for status/change 0.38–0.72/0.52–0.60 (WIPE-synovitis/effusion) and 0.68–0.89/0.78–0.85 (HIMRISS-synovitis/effusion). SRM was 1.23 for WIPE-osteitis, while lower for WIPE-synovitis/effusion and HIMRISS. Conclusion: MRI-WIPE and HIMRISS may after further validation be useful in future spondyloarthritis trials.

OriginalsprogEngelsk
TidsskriftSeminars in Arthritis and Rheumatism
Vol/bind51
Udgave nummer4
Sider (fra-til)940-945
ISSN0049-0172
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
RGWL has received consulting fees from CARE Arthritis, Parexel and Pfizer. WPM is Chief Medical Officer CARE Arthritis Limited and has acted as a paid consultant/participated in advisory boards for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB, received research and/or educational grants from AbbVie, Novartis, Pfizer and UCB, and received speaker fees from AbbVie, Janssen, Novartis, Pfizer and UCB. SJP has been an advisory board member for AbbVie and Novartis, received research support from AbbVie, MSD, and Novartis and speaker fees from MSD, Pfizer, AbbVie, Novartis and UCB. PB participated in advisory boards and received speaker fees from Janssen, Abbvie, UCB, Celgene, BMS, Novartis, Pfizer, Gilead, Eli-Lilly. HMO has received research grants from Janssen and Novartis, and honoraria/speaker fess from AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB. PC has received research grants from UCB, MSD and Pfizer, speaker/consultant fees for Pfizer, MSD, Novartis, BMS, AbbVie, UCB, Eli Lilly, Gilead and Celgene. PGC has received speaker or consultancy fees from AbbVie, AstraZeneca, BMS, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, Novartis, Pfizer and Stryker. MØ has received research support, consultancy fees and/or speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB. MW, IE, MS, SK, AJM, VF, FG, JP, GDM, AEFP and JLJ have no declarations for this work.

Funding Information:
We thank CARE Arthritis Limited (carearthritis.com) for help with setting up the web-based scoring interface, scoring exercises, and the web-based meetings. We acknowledge the contribution of SIG (Special Interest Group) participants at the virtual OMERACT meeting October 29, 2020. HMO, GDM and PGC are supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research center, United Kingdom. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding Information:
We thank CARE Arthritis Limited (carearthritis.com) for help with setting up the web-based scoring interface, scoring exercises, and the web-based meetings. We acknowledge the contribution of SIG (Special Interest Group) participants at the virtual OMERACT meeting October 29, 2020. HMO, GDM and PGC are supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research center, United Kingdom. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher Copyright:
© 2021 Elsevier Inc.

ID: 273651114